Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 6/20 | 0.37 |
| ▸ | BRAF | P15056 | 4/20 | 0.37 |
| ▸ | RAF1 | P04049 | 2/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 4/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3834620 | 0.90 | RET (0.39) | KDRFLT3SRCBRAFRAF1 | |
| SCHEMBL3239039 | 0.90 | RET (0.40) | KDRFLT3SRCBRAFRAF1 | |
| SCHEMBL3235234 | 0.89 | SRC (0.38) | KDRFLT3SRCBRAFRAF1 | |
| SCHEMBL3837288 | 0.84 | ALDH1A1 (0.45) | KDRFLT3SRCBRAFRAF1 | |
| SCHEMBL3240554 | 0.83 | EPHX2 (0.48) | KDRFLT3BRAFRAF1RET | |
| SCHEMBL3242770 | 0.81 | KDR (0.45) | KDRSRCBRAFRAF1 | |
| SCHEMBL3244888 | 0.81 | RIPK1 (0.42) | KDRFLT3SRCBRAFRAF1 | |
| SCHEMBL3836297 | 0.80 | RIPK1 (0.40) | KDRFLT3SRCBRAFRAF1 | |
| SCHEMBL3833067 | 0.80 | KDR (0.45) | KDRFLT3SRCBRAFRAF1 | |
| SCHEMBL3834618 | 0.79 | KDR (0.43) | KDRFLT3SRCBRAFRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1809630-B1 | 4-AMINO-5-OXO-8-PHENYL-5H-PYRIDO-[2,3-D]-PYRIMIDINE DERIVATIVES AS TYROSINE KINASE AND RAF KINASE INHIBITORS FOR THE TREATMENT OF TUMOURS | MERCK PATENT GMBH (DE) | 2009-04-15 | — | — | EP | claimed |
| US-20080146560-A1 | 4-Amino-5-Oxo-8-Phenyl-5H-Pyrido(2,3-D) Pyrimidine Derivatives as Tyrosine Kinase and Raf Kinase Inhibitors for the Treatment of Tumours | MERCK PATENT GMBH (DE) | 2008-06-19 | — | — | US | claimed |
| US-7745434-B2 | 4-Amino-5-oxo-8-phenyl-5H-pyrido(2,3-D) pyrimidine derivatives as tyrosine kinase and raf kinase inhibitors for the treatment of tumours | MERCK PATENT GMBH (DE) | 2010-06-29 | — | — | US | disclosed |
| US-20080146560-A1 | 4-Amino-5-Oxo-8-Phenyl-5H-Pyrido(2,3-D) Pyrimidine Derivatives as Tyrosine Kinase and Raf Kinase Inhibitors for the Treatment of Tumours | MERCK PATENT GMBH (DE) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146560-A1 | 4-Amino-5-Oxo-8-Phenyl-5H-Pyrido(2,3-D) Pyrimidine Derivatives as Tyrosine Kinase and Raf Kinase Inhibitors for the Treatment of Tumours | TIE1, PDXK, ERBB2 | KDR 8/4885FLT3 36/4885SRC 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.